About Bausch + Lomb
Founded in 1853 as an optical goods store in Rochester, New York, Bausch + Lomb is a global eye health company with a presence in nearly 100 countries and a workforce of approximately 13,000 employees.
For more than 170 years, Bausch + Lomb has maintained its dedication to innovations in eye health. The company’s portfolio includes a wide range of ophthalmic pharmaceuticals, over-the-counter eye care products and ophthalmic surgical instruments and devices.
Bausch + Lomb Under Brent Saunders’ Leadership
Brent first joined Bausch + Lomb in 2010, serving as CEO, president and a member of the board of directors until 2013. During that time, he successfully steered the company through significant change and restructuring. Brent then went on to serve in executive roles at Forest Laboratories and Actavis/Allergan, overseeing groundbreaking mergers and acquisitions, before returning to Bausch + Lomb as CEO and chairman of the board in 2023.
Under Brent’s leadership, Bausch + Lomb has seen significant growth. Notably, in 2023, Brent led the company’s acquisition of XIIDRA® and launch of MIEBO®, distinct prescription medications for the treatment of dry eye disease, a condition that impacts approximately 38 million U.S. adults.
Ambitious, forward-thinking eye health goals are the hallmark of Brent’s leadership of Bausch + Lomb. “When it comes to being an innovation company, we’re walking the walk and doing so with urgency and purpose,” he says.
Get the latest updates from Bausch + Lomb on Facebook, X, LinkedIn and Instagram.
